The intellectual property rights for Tamiflu are actually owned by a company called Gilead Sciences. Donald Rumsfeld was appointed Chairman of the
Board of Gilead in 1997, a post he held until becoming Secretary of Defence. Sources below indicate that that he still owns stock in Gilead and that
he may stand to profit substantially should a full blown pandemic occur.
Quote:
by Dr. Joseph Mercola
October 26, 2005
mercola.com
"We bring to the attention of Global Research readers this important commentary by Dr.Joseph Mercola.
The fundamnetal issue is who owns the intellectual property rights over Tamiflu. The media reports suggest that the Swiss pharmaceutical company
Roche will make billions.
While the drug is produced by Roche, it was developed by Gilead Sciences Inc.which owns the intellectual property rights. Gilead, which has maintained
a low profile, has outsourced the production to Roche.
Donald Rumsfeld was appointed Chairman of Gilead Sciences, Inc. in 1997, a position which he held in the years prior to becoming Secretary of
Defense.in the Bush adminstration. Rumsfeld had been on the Board of Directors from the establishment of Gilead in 1987.
As confirmed in a company press statement in 1997, Donald H. Rumsfeld assumed the position of Chairman, of GILEAD: :
"Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company's earliest days, and we are very pleased that he has
accepted the Chairmanship," Dr. Riordan said. "He has played an important role in helping to build and steer the company. His broad experience in
leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence."
According to company statement: Gilead Science Inc "has been active in the development of inhibitors for the potential treatment and prevention of
viral influenza and protease inhibitors for the potential treatment of HIV"
"The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and
genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery and development of
non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease
inhibitors for the potential treatment of HIV"
www.globalresearch.ca...
Quote:
"Since Rumsfeld holds major portions of stock in Gilead, he will handsomely profit from the scare tactics of the government that is being used to
justify the purchase of $2 billion of Tamiflu."
www.mercola.com...#



